Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Is Biogen a Buy After the Latest Aduhelm Disaster?
06:40am, Monday, 17'th Jan 2022
Only if you're (really) brave.
Where Will Biogen Be in 5 Years?
06:36am, Saturday, 15'th Jan 2022
The latest snub for Aduhelm does not bode well for this company's future.
Biogen Is More Likely to Be a Buyer Than Seller
03:56pm, Friday, 14'th Jan 2022
As the prospects for its once-promising Alzheimer's drug continue to dim, Biogen Inc. ( BIIB , Financial) is reportedly exploring strategic options, including selling itself or acquiring a smaller bio
Aurinia Pharmaceuticals reverses decline after report on potential M&A interest
07:49pm, Thursday, 13'th Jan 2022 Seeking Alpha
Aurinia Pharmaceuticals (AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (BIIB) could potentially look to target the company.Aurinia (AUPH) was
Biogen rebounds amid comments on M&A prospects (NASDAQ:BIIB)
07:27pm, Thursday, 13'th Jan 2022 Seeking Alpha
After a sharp selloff on Wednesday in reaction to an unfavorable Medicare decision on its new Alzheimer’s therapy, Aduhelm, Biogen <> have recovered as analysts weighed in on…
Denali Stock Tumbles; Why Biogen Isn''t The Only Alzheimer''s Play Under Pressure
05:31pm, Thursday, 13'th Jan 2022 Investor''s Business Daily
The Food and Drug Administration placed Denali''s Alzheimer''s test on hold Thursday, sending DNLI stock into a dive.
Biogen eyes potential acquisitions - Stat News
03:34pm, Thursday, 13'th Jan 2022
Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.
3 Biotech Stocks to Buy That Are Under Severe Pressure
11:27am, Thursday, 13'th Jan 2022
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.
Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug
08:01am, Thursday, 13'th Jan 2022
Shares of Biogen Inc. BIIB, -6.70% were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how
Dish Network, Ally Financial rise; Biogen, Carvana fall
09:24pm, Wednesday, 12'th Jan 2022 ABC News
Stocks that traded heavily or had substantial price changes Wednesday: Dish Network, Ally Financial rise; Biogen, Carvana fall
Wednesday Afternoon Analyst Upgrades and Downgrades: AbbVie, Biogen, DoorDash, Kratos Defense, PayPal and More
08:08pm, Wednesday, 12'th Jan 2022 24/7 Wall street
Wednesday afternoon''s top analyst upgrades and downgrades included AbbVie, Biogen, DoorDash, Kratos Defense, PayPal and more.
Proposal to limit Biogen''s Alzheimer''s drug followed evidence-based process - Medicare chief
07:11pm, Wednesday, 12'th Jan 2022 Seeking Alpha
The head of the body charged with administering Medicare said a proposed rule limiting access to Biogen''s (BIIB) controversial Alzheimer''s drug followed an evidence-based process.
Stocks making the biggest moves midday: DoorDash, Biogen, T. Rowe Price, Crocs and more
05:43pm, Wednesday, 12'th Jan 2022 CNBC
These are the stocks posting the largest moves in midday trading.
Why Biogen Stock Is Sinking Today
04:32pm, Wednesday, 12'th Jan 2022 The Motley Fool
A proposal would mean that most Medicare beneficiaries won''t have access to Biogen''s Alzheimer''s disease drug Aduhelm.
Biogen plans flood of public comments in response to Medicare decision - Endpoints
03:44pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Biogen plans to inundate the Centers for Medicare and Medicaid Services with public comments in response to the decision yesterday to drastically limit coverage of Aduhelm for Alzheimer''s.
